Saeed Omar, Jorde Ulrich P
From the Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
Cardiol Rev. 2017 Mar/Apr;25(2):84-88. doi: 10.1097/CRD.0000000000000117.
The purpose of this review is to highlight recent advances and challenges in the clinical implementation of continuous flow left ventricular assist devices (CF LVADs) in patients with advanced heart failure. Post approval studies of CF LVAD therapy continue to show a progressive improvement in survival and reduction in adverse events. Major trials are ongoing to compare outcomes of an axial flow device (Heart Mate II) and smaller centrifugal flow pumps (HeartWare VADs and Heart Mate III). Numerous studies have investigated strategies to reduce major hematologic and neurologic adverse events by evaluating hemolysis, antithrombotic therapy, and blood pressure control. This review will present the current findings that are centered around the impact of CF LVADs on improving survival and reducing adverse events through an evolution in management and design.
本综述的目的是强调晚期心力衰竭患者临床应用连续流左心室辅助装置（CF LVADs）的最新进展和挑战。CF LVAD治疗的批准后研究持续显示生存率逐步提高，不良事件减少。正在进行主要试验以比较轴流装置（HeartMate II）和较小的离心流泵（HeartWare VADs和HeartMate III）的结果。许多研究通过评估溶血、抗血栓治疗和血压控制来研究减少主要血液学和神经学不良事件的策略。本综述将介绍当前的研究结果，这些结果围绕CF LVADs通过管理和设计的演变对提高生存率和减少不良事件的影响展开。
Zotero 插件